Deferasirox removes cardiac iron and attenuates oxidative stress in the iron‐overloaded gerbil
Open Access
- 25 August 2009
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 84 (9), 565-570
- https://doi.org/10.1002/ajh.21487
Abstract
Iron-induced cardiovascular disease is the leading cause of death in iron-overloaded patients. Deferasirox is a novel, once daily oral iron chelator that was recently approved for the treatment of transfusional iron overload. Here, we investigate whether deferasirox is capable of removing cardiac iron and improving iron-induced pathogenesis of the heart using the iron overload gerbil model. Animals were randomly divided into three groups: control, iron overload, and iron overload + deferasirox treatment. Iron-dextran was given 100 mg/kg per 5 days i.p for 10 weeks. Deferasirox treatment was taken post iron loading and was given at 100 mg/kg/day p.o for 1 or 3 months. Cardiac iron concentration was determined by inductively coupled plasma atomic emission spectroscopy. Compared with the untreated group, deferasirox treatment for 1 and 3 months decreased cardiac iron concentration 17.1% (P = 0.159) and 23.5% (P < 0.05), respectively. These treatment-associated reductions in cardiac iron were paralleled by decreases in tissue ferritin expression of 20% and 38% at 1 and 3 months, respectively (P < 0.05). Using oxyblot analysis and hydroethidine fluorescence, we showed that deferasirox significantly reduces cardiac protein oxidation and superoxide abundance by 36 and 47.1%, respectively (P < 0.05). Iron-induced increase in oxidative stress was also associated with increased phosphorylation of ERK-, p38-, and JNK-mitogen-activated protein kinase (MAPK). Interestingly, deferasirox treatment significantly diminished the phosphorylation of all three MAPK subfamilies. These results suggest that deferasirox may confer a cardioprotective effect against iron induced injury. Am. J. Hematol. 2009.Keywords
This publication has 27 references indexed in Scilit:
- Clinical application of deferasirox: Practical patient managementAmerican Journal of Hematology, 2007
- Iron loading and its clinical implicationsAmerican Journal of Hematology, 2007
- Antioxidant-Mediated Effects in a Gerbil Model of Iron OverloadActa Haematologica, 2007
- Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbilTranslational Research, 2006
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questionsBlood, 2006
- Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants?Annals of the New York Academy of Sciences, 2005
- Objectives and Mechanism of Iron Chelation TherapyAnnals of the New York Academy of Sciences, 2005
- Taurine Supplementation Reduces Oxidative Stress and Improves Cardiovascular Function in an Iron-Overload Murine ModelCirculation, 2004
- Does the gerbil model mimic human iron overload?Journal of Laboratory and Clinical Medicine, 2003
- Cellular response to oxidative stress: Signaling for suicide and survival*Journal of Cellular Physiology, 2002